The Trump Rally: GOP Sweep Is Good News For Biopharma – But Don’t Get Carried Away
Executive Summary
Wall Street has made up its mind that the Nov. 8 US elections were great for biopharma companies. But is it really that clear cut?
You may also be interested in...
Drug Affordability Review By National Academies Kicks Off With Lower Profile Than Expected
A National Academies of Sciences, Engineering and Medicine project on drug access and affordability is kicking off with a very different political backdrop for its deliberations than the one that seemed likely when the working group was selected in late October; its work may still end up mattering a great deal, if and when innovator pricing is back on the table for serious policy review.
A New Idea To Solve The Turing Problem – If Anyone Notices
The Fair Pricing Coalition previewed its upcoming ‘first hundred days’ proposal for drug pricing reforms – one of many Washington policy documents that was prepared with a very different election result in mind. But one new idea in the report deserves serious attention because it would actually directly address the ‘repricing’ strategy that drove the headlines over the past year.
A New Idea To Solve The Turing Problem – If Anyone Notices
The Fair Pricing Coalition previewed its upcoming ‘first hundred days’ proposal for drug pricing reforms – one of many Washington policy documents that was prepared with a very different election result in mind. But one new idea in the report deserves serious attention because it would actually directly address the ‘repricing’ strategy that drove the headlines over the past year.